Literature DB >> 17169241

Statin therapy: is the percent reduction or the attained low-density lipoprotein cholesterol level more important?

Tracie C Collins1, Peter H Jones.   

Abstract

Hyperlipidemia is a well-known risk factor for atherosclerosis. Several trials have demonstrated the importance of lowering low-density lipoprotein cholesterol (LDL-C) levels to reduce all-cause mortality, coronary ischemia, and cerebrovascular accidents. Although the optimal goal for LDL-C levels in patients with known coronary heart disease has been less than 100 mg/dL, more recent findings support achieving even lower LDL-C levels for very high-risk patients. As the target levels for LDL-C trend towards lower values, it is important to evaluate the status for optimal management with statin therapy. In this review article, we discuss the role of percent LDL-C reduction versus attained LDL-C levels as targets for statin therapy in order to maximize the preventive care provided to high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17169241     DOI: 10.1007/bf02693935

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  25 in total

Review 1.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

Authors:  James H O'Keefe; Loren Cordain; William H Harris; Richard M Moe; Robert Vogel
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

2.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

Authors:  Sidney C Smith; Jerilyn Allen; Steven N Blair; Robert O Bonow; Lawrence M Brass; Gregg C Fonarow; Scott M Grundy; Loren Hiratzka; Daniel Jones; Harlan M Krumholz; Lori Mosca; Richard C Pasternak; Thomas Pearson; Marc A Pfeffer; Kathryn A Taubert
Journal:  Circulation       Date:  2006-05-16       Impact factor: 29.690

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

4.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

7.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

8.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.